Blastic plasmacytoid dendritic cell neoplasm complicated with acute myeloid leukemia: a case report

Blastic plasmacytoid dendritic cell neoplasm （BPDCN） complicated with acute myeloid leukemia （AML） is a rare disease. In this article， we reported the diagnosis and treatment of one patient of BPDCN complicated with AML who presented with fever as the first symptom， aiming to enhance the diagnostic and therapeutic capability of clinicians for this disease. The male patient， aged 69 years old， was admitted to hospital due to fever for 1 week. He had no typical skin lesions. Morphological and cytological observation of bone marrow smear showed extremely active hyperplasia and tumor cells with specific immunophenotype. The diagnosis of BPDCN complicated with AML was confirmed. A low-intensity venetoclax-based chemotherapy regimen was recommended. However， the patient discontinued further treatment

Identification of DYNLT1 associated with proliferation, relapse, and metastasis in breast cancer

BackgroundBreast cancer (BC) is the most common malignant disease worldwide. Although the survival rate is improved in recent years, the prognosis is still bleak once recurrence and metastasis occur. It is vital to investigate more efficient biomarkers for predicting the metastasis and relapse of BC. DYNLT1 has been reported that participating in the progression of multiple cancers. However, there is still a lack of study about the correlation between DYNLT1 and BC.MethodsIn this study, we evaluated and validated the expression pattern and prognostic implication of DYNLT1 in BC with multiple public cohorts and BC tumor microarrays (TMAs) of paraffin-embedded tissues collected from the Affiliated Hospital of Jining Medical University. The response biomarkers for immune therapy, such as tumor mutational burden (TMB), between different DYNLT1 expression level BC samples were investigated using data from the TCGA-BRCA cohort utilizing public online tools. In addition, colony formation and transwell assay were conducted to verify the effects of DYNLT1 in BC cell line proliferation and invasion.ResultsThe results demonstrated that DYNLT1 overexpressed in BC and predicted poor relapse-free survival in our own BC TMA cohort. In addition, DYNLT1 induced BC development by promoting MDA-MB-231 cell proliferation migration, and metastasis.ConclusionAltogether, our findings proposed that DYNLT1 could be a diagnostic and prognostic indicator in BC

Actively implementing an evidence-based feeding guideline for critically ill patients (NEED): a multicenter, cluster-randomized, controlled trial

Background: Previous cluster-randomized controlled trials evaluating the impact of implementing evidence-based guidelines for nutrition therapy in critical illness do not consistently demonstrate patient benefits. A large-scale, sufficiently powered study is therefore warranted to ascertain the effects of guideline implementation on patient-centered outcomes. Methods: We conducted a multicenter, cluster-randomized, parallel-controlled trial in intensive care units (ICUs) across China. We developed an evidence-based feeding guideline. ICUs randomly allocated to the guideline group formed a local "intervention team", which actively implemented the guideline using standardized educational materials, a graphical feeding protocol, and live online education outreach meetings conducted by members of the study management committee. ICUs assigned to the control group remained unaware of the guideline content. All ICUs enrolled patients who were expected to stay in the ICU longer than seven days. The primary outcome was all-cause mortality within 28 days of enrollment. Results: Forty-eight ICUs were randomized to the guideline group and 49 to the control group. From March 2018 to July 2019, the guideline ICUs enrolled 1399 patients, and the control ICUs enrolled 1373 patients. Implementation of the guideline resulted in significantly earlier EN initiation (1.20 vs. 1.55 mean days to initiation of EN; difference − 0.40 [95% CI − 0.71 to − 0.09]; P = 0.01) and delayed PN initiation (1.29 vs. 0.80 mean days to start of PN; difference 1.06 [95% CI 0.44 to 1.67]; P = 0.001). There was no significant difference in 28-day mortality (14.2% vs. 15.2%; difference − 1.6% [95% CI − 4.3% to 1.2%]; P = 0.42) between groups. Conclusions: In this large-scale, multicenter trial, active implementation of an evidence-based feeding guideline reduced the time to commencement of EN and overall PN use but did not translate to a reduction in mortality from critical illness. Trial registration: ISRCTN, ISRCTN12233792. Registered November 20th, 2017

Actively implementing an evidence-based feeding guideline for critically ill patients (NEED): a multicenter, cluster-randomized, controlled trial (vol 26, 46, 2022)

BackgroundPrevious cluster-randomized controlled trials evaluating the impact of implementing evidence-based guidelines for nutrition therapy in critical illness do not consistently demonstrate patient benefits. A large-scale, sufficiently powered study is therefore warranted to ascertain the effects of guideline implementation on patient-centered outcomes.MethodsWe conducted a multicenter, cluster-randomized, parallel-controlled trial in intensive care units (ICUs) across China. We developed an evidence-based feeding guideline. ICUs randomly allocated to the guideline group formed a local "intervention team", which actively implemented the guideline using standardized educational materials, a graphical feeding protocol, and live online education outreach meetings conducted by members of the study management committee. ICUs assigned to the control group remained unaware of the guideline content. All ICUs enrolled patients who were expected to stay in the ICU longer than seven days. The primary outcome was all-cause mortality within 28 days of enrollment.ResultsForty-eight ICUs were randomized to the guideline group and 49 to the control group. From March 2018 to July 2019, the guideline ICUs enrolled 1399 patients, and the control ICUs enrolled 1373 patients. Implementation of the guideline resulted in significantly earlier EN initiation (1.20 vs. 1.55 mean days to initiation of EN; difference - 0.40 [95% CI - 0.71 to - 0.09]; P = 0.01) and delayed PN initiation (1.29 vs. 0.80 mean days to start of PN; difference 1.06 [95% CI 0.44 to 1.67]; P = 0.001). There was no significant difference in 28-day mortality (14.2% vs. 15.2%; difference - 1.6% [95% CI - 4.3% to 1.2%]; P = 0.42) between groups.ConclusionsIn this large-scale, multicenter trial, active implementation of an evidence-based feeding guideline reduced the time to commencement of EN and overall PN use but did not translate to a reduction in mortality from critical illness.Trial registrationISRCTN, ISRCTN12233792 . Registered November 20th, 2017

Actively implementing an evidence-based feeding guideline for critically ill patients (NEED): a multicenter, cluster-randomized, controlled trial.

BackgroundPrevious cluster-randomized controlled trials evaluating the impact of implementing evidence-based guidelines for nutrition therapy in critical illness do not consistently demonstrate patient benefits. A large-scale, sufficiently powered study is therefore warranted to ascertain the effects of guideline implementation on patient-centered outcomes.MethodsWe conducted a multicenter, cluster-randomized, parallel-controlled trial in intensive care units (ICUs) across China. We developed an evidence-based feeding guideline. ICUs randomly allocated to the guideline group formed a local "intervention team", which actively implemented the guideline using standardized educational materials, a graphical feeding protocol, and live online education outreach meetings conducted by members of the study management committee. ICUs assigned to the control group remained unaware of the guideline content. All ICUs enrolled patients who were expected to stay in the ICU longer than seven days. The primary outcome was all-cause mortality within 28 days of enrollment.ResultsForty-eight ICUs were randomized to the guideline group and 49 to the control group. From March 2018 to July 2019, the guideline ICUs enrolled 1399 patients, and the control ICUs enrolled 1373 patients. Implementation of the guideline resulted in significantly earlier EN initiation (1.20 vs. 1.55 mean days to initiation of EN; difference - 0.40 [95% CI - 0.71 to - 0.09]; P = 0.01) and delayed PN initiation (1.29 vs. 0.80 mean days to start of PN; difference 1.06 [95% CI 0.44 to 1.67]; P = 0.001). There was no significant difference in 28-day mortality (14.2% vs. 15.2%; difference - 1.6% [95% CI - 4.3% to 1.2%]; P = 0.42) between groups.ConclusionsIn this large-scale, multicenter trial, active implementation of an evidence-based feeding guideline reduced the time to commencement of EN and overall PN use but did not translate to a reduction in mortality from critical illness.Trial registrationISRCTN, ISRCTN12233792 . Registered November 20th, 2017

Investigation of the hydrate formation process in fine sediments by a binary CO2/N-2 gas mixture

To obtain the fundamental data of CO2/N-2 gas mixture hydrate formation kinetics and CO2 separation and sequestration mechanisms, the gas hydrate formation process by a binary CO2/N-2 gas mixture (50:50) in fine sediments (150-250 mu m) was investigated in a semibatch vessel at variable temperatures(273, 275, and 277 K)and pressures (5.8-7.8 MPa). During the gas hydrate reaction process, the changes in the gaseous phase composition were determined by gas chromatography. The results indicate that the gas hydrate formation process of the binary CO2/N-2 gas mixture in fine sediments can be reduced to two stages. Firstly, the dissolved gas containing a large amount of CO2 formed gas hydrates, and then gaseous N-2 participated in the gas hydrate formation. In the second stage, all the dissolved gas was consumed. Thus, both gaseous CO2 and N-2 diffused into sediment. The first stage in different experiments lasted for 5-15 h, and >60% of the gas was consumed in this period. The gas consumption rate was greater in the first stage than in the second stage. After the completion of gas hydrate formation, the CO2 content in the gas hydrate was more than that in the gas phase. This indicates that CO2 formed hydrate easily than N-2 in the binary mixture. Higher operating pressures and lower temperatures increased the gas consumption rate of the binary gas mixture in gas hydrate formation. (C) 2019 The Chemical Industry and Engineering Society of China, and Chemical Industry Press Co., Ltd. All rights reserved

CO2 removal from synthesized ternary gas mixtures used hydrate formation with sodium dodecyl sulfate(SDS) as additive

In order to investigate the hydrate formation kinetics of the ternary gas mixtures containing sodium dodecyl sulfate (SDS) and evaluate the applicability of hydrate based gas separation (HBGS) technology to biogas, synthesized ternary gas mixture (CH4/CO2N2) hydrate formation processes with different concentrations of SDS were investigated comprehensively in this work. The changes in the gas composition during the hydrate formation process, the gas consumption of the hydrate, the effective reaction time, the recovery factor of CH4, the split ratio of CO2, and the microscopic promotion mechanism of SDS for the hydrate were studied. The results indicated that the addition of SDS increased the hydrate reaction rate and gas consumption compared with those in a pure water system. The promotional effect of SDS improved with an increase in its concentration. The maximum CO2 split ratio was 0.95, at a driving force of 4.4 MPa and 0.05% SDS concentration. The maximum CH4 recovery factor was 3.18, at a driving force of 6.4 MPa and 0.03% SDS concentration. SDS promoted the formation of CO2 hydrate more strongly than that of CH4 and N-2 for the ternary gas mixture. In summary, HBGS technology exhibited a good separation effect under two experimental conditions. (C) 2019 Elsevier Ltd. All rights reserved

One-step hydrothermal synthesis of g-C

In this work, a ternary composite photocatalyst with layer structure was synthesized by a one-step hydrothermal method. The visible-light-driven layered ternary photocatalyst exhibited excellent photocatalytic performance for the degradation of tetracycline (TC). The degradation rate of TC reached 88.78% within 60 min under visible light exposure in presence of optimum ratio G-T-B-0.2, which is higher than pure g-C3N4, TiO2 and BiOBr. Scaning electron microscope (SEM), Transmission electron microscope (TEM), Xray diffractometer (XRD), Fourier transform infrared spectra (FTIR), spectrometer and X-ray photoelectron spectroscopy (XPS) were used to character the physicochemical properties of the synthesized samples. Photoelectrochemical measurements and radical trapping experiments revealed that the improvement of photocatalytic performance was mainly attributed to the rapid charge transfer at the interface of gC3N4/TiO2/BiOBr, which was benefit to the separation of photogenerated carriers and visible light absorption. This work provides a facile method for the synthesis of ternary heterojunctions, which has potential applications in environmental remediation